<DOC>
	<DOC>NCT00216177</DOC>
	<brief_summary>The purpose of this study is to establish whether RA patients with moderate to severe disease activity with unsustainable response to infliximab 3 mg/kg every 8 weeks have better efficacy with adalimumab 40 mg s.c. eow compared to infliximab 3 mg/kg i.v. every 6 weeks.</brief_summary>
	<brief_title>Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>ACR criteria fulfilled,DAS283(CRP &gt; 3.2 &gt; 6 months prior treatment with infliximab 3 mg/kg i.v. every 8 week with initial response Fading clinical response to infliximab Negative pregnancy test (women with childbearing potential) Use of reliable method of contraception (women with childbearing potential) Informed consent Age less than 18 years Lack of cooperability Positive serology for hepatitis B or C History of positive HIV status History of TB or untreated latent TB Histoplasmosis or Listeriosis Pregnancy or breastfeeding Persistent or recurrent infections History of cancer Uncontrolled diabetes Ischaemic heart disease Congestive heart failure (NYHA 34) Active inflammatory bowel disease Recent stroke (within 3 months) History of or current inflammatory joint disease other than RA Previous diagnosis or signs of central nervous system demyelinating disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>